Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
10/4/2024 | $59.00 → $85.00 | Hold → Buy | TD Cowen | |
10/3/2024 | $392.00 → $274.00 | Overweight → Neutral | Piper Sandler | |
10/2/2024 | $376.00 → $247.00 | Neutral → Underperform | BofA Securities | |
10/2/2024 | $400.00 → $250.00 | Outperform → Market Perform | Leerink Partners | |
10/2/2024 | $400.00 → $250.00 | Overweight → Equal-Weight | Stephens | |
9/13/2024 | $1060.00 | Buy | Citigroup | |
8/12/2024 | $1025.00 | Hold → Buy | Deutsche Bank | |
7/17/2024 | $555.00 → $615.00 | Outperform | RBC Capital Mkts |
8-K - HUMANA INC (0000049071) (Filer)
8-K - GoHealth, Inc. (0001808220) (Filer)
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
BLOOMFIELD, Conn., Oct. 3, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2024 financial results on Thursday, October 31, 2024, and will host a conference call the same day. Third quarter 2024 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows: Live Call (888) 566-1889 (Domestic) (773) 799-3989 (International) Passcode: 103
Humana Inc. (NYSE:HUM) will release its financial results for the third quarter 2024 (3Q24), as well as prepared management remarks (in PDF format), on Wednesday, October 30, 2024, at 6:30 a.m. Eastern time. The company will host a live question and answer session at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2024. To participate via telephone, please register in advance using this link, https://register.vevent.com/register/BI66effa11b1e4494d907df29b87d7d237. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique regi
WOONSOCKET, R.I., Sept. 19, 2024 /PRNewswire/ -- CVS Health (NYSE:CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on November 1, 2024, to holders of record on October 21, 2024. About CVS HealthCVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support i
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr
TD Cowen upgraded CVS Health from Hold to Buy and set a new price target of $85.00 from $59.00 previously
Piper Sandler downgraded Humana from Overweight to Neutral and set a new price target of $274.00 from $392.00 previously
BofA Securities downgraded Humana from Neutral to Underperform and set a new price target of $247.00 from $376.00 previously
UnitedHealthcare today announced a $335,000 commitment in funding to Idaho organizations to help close gaps in care among underserved communities, including people in rural areas, individuals with chronic conditions and seniors. "Expanding programs for caregivers, community health workers and providers allows us to address unmet health needs more effectively, helping to ensure that underserved communities access high-quality care and social services they need," said Dr. Alex Billioux, Government Programs Chief Medical Officer, UnitedHealthcare. "By equipping our health care workers with the necessary resources and training, we can help improve health outcomes and quality of life for all Id
BLOOMFIELD, Conn., Oct. 3, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2024 financial results on Thursday, October 31, 2024, and will host a conference call the same day. Third quarter 2024 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows: Live Call (888) 566-1889 (Domestic) (773) 799-3989 (International) Passcode: 103
For the third year, CVS Pharmacy is offering 60+ allergy-friendly treats in stores and online McLEAN, Va. and WOONSOCKET, R.I., Oct. 3, 2024 /PRNewswire/ -- FARE (Food Allergy Research & Education), the leading nonprofit organization engaged in food allergy education and advocacy — and the largest provider of charitable support for food allergy research in the U.S. — is partnering with CVS Pharmacy®, a CVS Health® company (NYSE:CVS), for the third consecutive year on the Teal Pumpkin Project, a movement creating a more inclusive Halloween for those with food allergies by offering an expanded selection of non-food treats.
SC 13G/A - HUMANA INC (0000049071) (Subject)
SC 13G/A - eHealth, Inc. (0001333493) (Subject)
SC 13G/A - eHealth, Inc. (0001333493) (Subject)
The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso
4 - eHealth, Inc. (0001333493) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - eHealth, Inc. (0001333493) (Issuer)
4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)
4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)
4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)
FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health" or "Clover"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph Brand as Chief Operating Officer (COO) for its Medicare Advantage (MA) plan. Mr. Brand will oversee core MA operations and drive performance improvements, with a focus on improving healthcare delivery in New Jersey by leveraging operational efficiencies and technological innovation. Mr. Brand brings nearly 20 years of healthcare leadership experience, having held prominent positions in healthcare operation
AUSTIN, Texas, Sept. 24, 2024 /PRNewswire/ -- eHealth, Inc. (NASDAQ:EHTH) (eHealth.com), a leading private online health insurance marketplace, today announced the appointment of Prama Bhatt as a Class II director and independent member of the eHealth Board of Directors (the "Board"), effective September 24, 2024. Ms. Bhatt will also serve on the Audit Committee and the Government and Regulatory Affairs Committee of the Board. Her initial term will run until the Annual Meeting of Stockholders in 2026. "We are pleased to welcome Prama to our Board of Directors," said Fran Soistman, CEO of eHealth. "Her deep expertise in digital innovation and customer retention and growth strategies will be i
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 62% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $155,555 and 5, calls, for a total amount of $255,360. What's The Price Target? Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $175.0 for Novo Nordisk during the past quarter. Analyzing Volume & Open Interest Assessing
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 15 years by 11.36% on an annualized basis producing an average annual return of 23.33%. Currently, Eli Lilly and Co has a market capitalization of $730.31 billion. Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 15 years ago, it would be worth $23,116.69 today based on a price of $811.09 for LLY at the time of writing. Eli Lilly and Co's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automat